Drug Trial Radar · NCT04956640
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Jul 19, 2021
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jul 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Conditions
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Endometrial Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Biliary Tract Neoplasms
Interventions
LY3537982Drug
Oral
PembrolizumabDrug
Intravenous
CetuximabDrug
Intravenous
PemetrexedDrug
Intravenous
CisplatinDrug
Intravenous
CarboplatinDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapyTime frame: Cycle 1 (21 Days)
- Phase 1b: To assess the safety and tolerability of LY3537982 when administered alone or in combination with other investigational agentsTime frame: Cycle 1 (21 Days)
- Phase 1b: To determine the optimal dose of LY3537982 to be administered to treatment-naïve participants with advanced NSCLC in combination with pembrolizumabTime frame: Estimated up to 2 years
- To determine the optimal dose of LY3537982 to be administered to participants who have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC in combination with cetuximabTime frame: Estimated up to 2 years
- To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutationTime frame: Estimated up to 2 years
Locations
49 sites in 6 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
USC Norris Cancer Hospital
Los Angeles, California
Chao Family Comprehensive Cancer Ctr.
Orange, California
Yale-New Haven Hospital
New Haven, Connecticut
AdventHealth Orlando
Orlando, Florida
Florida Cancer Specialists
Sarasota, Florida
Indiana Univ Melvin & Bren Simon Cancer Center
Indianapolis, Indiana
Community Health Network
Indianapolis, Indiana
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana
Massachusetts General Hospital
Boston, Massachusetts
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
NYU Langone Health- Long Island
Mineola, New York
NYU Langone
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Novant Health Cancer Institute - Elizabeth
Charlotte, North Carolina
Novant Health Cancer Institute - Forsyth
Winston-Salem, North Carolina
Fox Chase Cancer Center
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Sarah Cannon Cancer Center
Nashville, Tennessee
Vanderbilt Univeristy School of Medicine
Nashville, Tennessee
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas
START Mountain Region
West Valley City, Utah
Inova Health System IRB
Fairfax, Virginia
USO-Virginia Cancer Specialists, PC
Fairfax, Virginia
University of Wisconsin-Madison Hospital and Health Clinic
Madison, Wisconsin
Royal North Shore Hospital
St Leonards, New South Wales, Australia
St Vincent's Hospital Sydney
Sydney, New South Wales, Australia
Cancer Research SA
Adelaide, South Australia, Australia
Peninsula and Southeast Oncology
Frankston, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Cross Cancer Institute
Edmonton, Alberta, Canada
Princess Margaret Hospital (Ontario)
Toronto, Ontario, Canada
Institut du Cancer de Montpellier - Val d'aurelle
Montpellier, France
Institut Claudius Regaud - IUCT Oncopole
Toulouse, France
Gustave Roussy
Villejuif, France
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
Bordeaux, Aquitaine, France
Centre Leon Berard
Lyon, Auvergne-Rhône-Alpes, France
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.